RxDoctor Payments DataLook up a doctor →

Michael Gesquiere, MD

Anesthesiology · Centennial, CONPI 1245203090

Payments from drug & device makers

$19,767in general payments, 2019–2025

Across 386 payments — averaging $51.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • AbbVie$1K
  • SPR Therapeutics, Inc$1K
  • Boston Scientific$532
  • Abbott$485
  • Scilex Pharmaceuticals Inc.$388
  • plus $4K from 33 others
$820in research payments, 2019–2025

Across 1 payment — averaging $820.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$820

What the payments were for

  • Speaking & faculty fees$8,26342%
  • Food & beverage$11,50558%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,767 in reported general payments places this provider in the 95th percentile of 921 anesthesiology providers in Colorado.

See all anesthesiology providers in Colorado

Medicare billing

Part B allowed, 2024
$198,536
Medicare patients
280
Services billed
7,826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl33$17,695
BelbucaBuprenorphine Hcl17$12,515
Xtampza ErOxycodone Myristate23$10,289
NucyntaTapentadol Hcl11$9,766
Buprenorphine39$7,464
ZtlidoLidocaine12$6,442
MovantikNaloxegol Oxalate11$5,413
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen100$2,935
Oxycodone Hcl116$2,383
Gabapentin98$2,139
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen74$1,945
Morphine Sulfate ErMorphine Sulfate50$1,577
Celecoxib24$1,570
Tizanidine Hcl83$992
Cyclobenzaprine Hcl40$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$183$32,56951 claims
Scilex Pharmaceuticals Inc.Ztlido$388$6,44212 claims
Redhill Biopharma Inc.Movantik$14$5,41311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 921 anesthesiology providers in Colorado.

Other anesthesiology in Centennial

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →